Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer

References

• American Cancer Society. Breast Cancer Overview. Atlanta: American Cancer Society, 2009. Available at http://www.cancer.org/cancer/breastcancer/overviewguide/breast-cancer-overview-key-statistics. [Last accessed 12 September 2010]
   Google Scholar
• Ries LAG, Melbert D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008. [Last accessed 27 November, 2009]
   Google Scholar
• Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205
   PubMed Web of Science ®Google Scholar
• Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period. Cancer 2005;104:1742-1750
   PubMed Web of Science ®Google Scholar
• Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004;100:44-52
   PubMed Web of Science ®Google Scholar
• Osoba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20:3106-3113
   PubMed Web of Science ®Google Scholar
• Grabsch B, Clarke DM, Love A, et al. Psychological morbidity and quality of life in women with advanced breast cancer: a cross-sectional survey. Palliat Support Care 2006;4:47-56
   PubMedGoogle Scholar
• Facchini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res 2007;26:307-312
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;3:CD003474
   Google Scholar
• Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus 2004;16:E8
   Google Scholar
• Morrow M, Goldstein L. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? J Clin Oncol 2006;24:2694-2696
   Google Scholar
• Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005;123:21-27
   PubMed Web of Science ®Google Scholar
• Possinger K. Fulvestrant: a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer. Expert Opin Pharmacother 2004;5:2549-2558
   PubMed Web of Science ®Google Scholar
• NCCN: National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer, v2.2008. Available at http://www.nccn.org. [Last accessed 3 November 2009]
   Google Scholar
• Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215-225
   PubMed Web of Science ®Google Scholar
• Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003;2:CD002747
   PubMedGoogle Scholar
• Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008;26:798-805
   PubMed Web of Science ®Google Scholar
• Jazaeri AA, Maxwell GL, Rice LW. Hormones and human malignancies. In: Hoskins WJ, Perez CA, Young RC, et al., Principles and Practice of Gynecologic Oncology, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:17
   Google Scholar
• Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008;19:16-27
   PubMed Web of Science ®Google Scholar
• Smith I, Chua S. Medical treatment of early breast cancer. IV: neoadjuvant treatment. BMJ 2006;332:223-224
   Google Scholar
• ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003;98:1802-1810
   Google Scholar
• Rau KM, Kang HY, Cha TL, et al. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 2005;12:511-532
   PubMed Web of Science ®Google Scholar
• Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-658
   PubMed Web of Science ®Google Scholar
• Yanagitani N, Shimizu Y, Kaira K, et al. Pulmonary toxicity associated with vinorelbine-based chemotherapy in breast cancer. Gan To Kagaku Ryoho 2008;35:1619-1621
   Google Scholar
• Philippin-Lauridant G, Thureau S, Ouvrier MJ, et al. Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel. Ann Oncol 2008;19:1977-1978
   Google Scholar
• Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer – the need for vigilance. J Natl Cancer Inst 2006;98:1096-1097
   PubMed Web of Science ®Google Scholar
• Welch HG, Fisher ES. Diagnostic testing following screening mammography in the elderly. J Natl Cancer Inst 1998;90:1389-1392
   PubMedGoogle Scholar
• Dang, C. Hormonal therapy: current status in the treatment of metastatic breast cancer. Continuing medical information. Available at http://www.cancernetwork.com/display-cme/article/10165/62333. [Last accessed September 20, 2010]
   Google Scholar
• D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-387
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Zhang HF, et al. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. J Manag Care Pharm 2007;13:561-569
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Databases, tables & calculators by subject: Inflation and Prices. Available at http://www.bls.gov/data/#prices [Last accessed September 20, 2010]
   Google Scholar
• Lin DY. Linear regression analysis of censored medical costs. Biostatistics 2000;1:35-47
   PubMedGoogle Scholar
• Susan G. Komen Foundation. Recommended Treatments for Metastatic Breast Cancer. Available at http://ww5.komen.org/BreastCancer/RecommendedTreatmentsforMetastaticBreastCancer.html [Last Accessed September 20, 2010]
   Google Scholar
• Boccardo F, Rubagotti, A, Amoroso D, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 1992;28:673-680
   Google Scholar
• Huober J, Fasching P, Paepke S, et al. Letrozole in combination with trastuzumab is superior to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC) – Results of the eLEcTRA trial. Cancer Res 2009;69: Abstract nr 4094
   Google Scholar
• Giordano SH, Buzdar AU, Kau SC, Hortobagyi GN. Improvement in breast cancer survival: results from M. D. Anderson Cancer Center protocols from 1975–2000. Presented at ASCO, 2002 Abstract No: 212
   Google Scholar
• Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 2004;83:25-32
   PubMed Web of Science ®Google Scholar
• Wai ES, Trevisan CH, Taylor SCM, et al. Health system costs of metastatic breast cancer. Breast Cancer Res Treat 2001;65:233-240
   Google Scholar
• Cocquyt V, Moeremans K, Annemans L, et al. Long-term medical costs of post-menopausal breast cancer therapy. Ann Oncol 2003;14:1057-1063
   Google Scholar
• Legorreta AP, Brooks RJ, Leibowitz AN, et al. Cost of breast cancer treatment: a 4-year longitudinal study. Arch Intern Med 1996;156:2197-2201
   Google Scholar
• Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-434
   PubMed Web of Science ®Google Scholar
• Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika 2000;87:329-343
   Web of Science ®Google Scholar
• Baser O, Gardiner JC, Bradley CJ, et al. Longitudinal analysis of censored medical cost data. Health Econ 2006;15:513-525
   PubMed Web of Science ®Google Scholar
• Raikou M, McGuire A. Estimating medical care costs under conditions of censoring. J Health Econ 2004;23:443-470
   PubMed Web of Science ®Google Scholar
• O'Hagan A, Stevens JW. On estimators of medical costs with censored data. J Health Econ 2004;23:615-625
   PubMed Web of Science ®Google Scholar
• Young TA. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 2005;23:1229-1242
   PubMed Web of Science ®Google Scholar